Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation est conditio cutanea pigmento aucta in cute post inflammationem. Postinflammatory hyperpigmentation potest oriri ex diuturno sole vel nuditate, inflammatione vel aliis cutis iniuriis, etiam ex acne cognatae. Homines cum cutis tonis obscurioribus proniores sunt ad hyperpigmentationem, praesertim cum excessu expositionis ad solem nudum.
☆ AI Dermatology — Free Service
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
relevance score : -100.0%
ReferencesPostinflammatory hyperpigmentation (PIH) est crebra cutis problema, quod post inflammationem cutis aut laesionem fit. Longum tempus durare potest, et in hominibus cum tono cutis obscuriori (Fitzpatrick skin types III–VI) est peior. Quamvis saepe se ipsa convalescat, tamen ad tempus sumere potest, ut saepe diuturnam curationem requirat. Diversae curationes optimae componendae sunt.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatio hyperpigmentatio communis est sequela inflammationis cutis. Afectat homines magis ac saepius obscuriores cutis, tendens ad callositatem. Studia monstrant quaestiones similes postinflammatio hyperpigmentatio esse inter praecipuas causas curarum hominum cum tonis obscurioribus cutis, qui curam dermatologicam quaerunt. Praeparatio praematura pendet ad solvendum postinflammatio hyperpigmentatio et plerumque incipit cum administratione conditionis inflammationis initialis. Prima linea curationis typice involvit usum agentium topicarum quae cutem una cum sunscreen (protectio solaris) illustrant. Haec agentia, sicut hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts, efficaciter pigmentationem excessivam minuere possunt. Accedunt retinoides, mequinol, ascorbic acid, niacinamide, N‑acetyl‑glucosamine, soy, etiam ut agentia depigmentanda adhibentur, cum novae curationes emergunt. Cum curationes topicae efficaces solent ad hyperpigmentationem superficiei gradus, rationes (laser, chemical peel) necessariae sunt in casibus contumacibus. Gravis est cavere cum his curationibus, ut irritatio et peioratio postinflammatory hyperpigmentatione vitetur.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
